← Leaderboards
Robert Zygmunt Orlowski
University Of North Carolina Chapel Hill
$7,581,271
Attributed
$8,539,907
Total exposure
15
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$19,637,406 · 16
By mechanism
P50$12,727,577 · 4
R01$6,680,751 · 4
P30$146,869 · 1
M01$82,209 · 7
Top collaborators
- Javeed Iqbal4 shared
Most similar at University Of North Carolina Chapel Hill
Same institution · by research overlap
- Blossom A Damania$35,988,246
- Kiran N Mahajan$1,329,949
- Jane Clowney Schroeder$262,801
Others in their field
Top investigators on “Multiple Myeloma”
- David Heimbrook · Leidos Biomedical Research, Inc.$146,380,351
- Larry Arthur$41,717,333
- Charles A Coltman · Southwest Oncology Group$36,988,659
- Kenneth C Anderson · Dana-Farber Cancer Inst$25,497,347
- Irene M. Ghobrial · Dana-Farber Cancer Inst$22,402,686
- Nilsa Del Carmen Ramirez · Ohio State University$22,287,552
Research focus
Multiple MyelomaHematologic NeoplasmsClinicMolecularPathway InteractionsTranslatingProgramsPharmaceutical PreparationsTumorCellsApoptoticResearch PersonnelDiagnosisBasePlasma CellsMemberIn VivoIn Vivo ModelApoptosisCollaborationsRelapseFundingLymphomaClinical Trials
Grant awards (58)
Role of Heat Shock Protein 70 as a Mediator and Therapeutic Target in T-cell Lymphomas$483,912
R01 · FY2025 · CA · contact PI
12 Hematologic Malignancies$24,690
P30 · FY2025 · CA · contact PI
Role of Heat Shock Protein 70 as a Mediator and Therapeutic Target in T-cell Lymphomas$459,716
R01 · FY2024 · CA · contact PI
12 Hematologic Malignancies$23,220
P30 · FY2024 · CA · contact PI
Role of Heat Shock Protein 70 as a Mediator and Therapeutic Target in T-cell Lymphomas$474,235
R01 · FY2023 · CA · contact PI
12 Hematologic Malignancies$18,707
P30 · FY2023 · CA · contact PI
Role of Heat Shock Protein 70 as a Mediator and Therapeutic Target in T-cell Lymphomas$499,410
R01 · FY2022 · CA · contact PI
12 Hematologic Malignancies$18,707
P30 · FY2022 · CA · contact PI
12 Hematologic Malignancies$18,707
P30 · FY2021 · CA · contact PI
Proteasome Assembly Chaperones in Sensitivity and Resistance to Proteasome Inhibitors$359,851
R01 · FY2020 · CA · contact PI
12 Hematologic Malignancies$18,676
P30 · FY2020 · CA · contact PI
Proteasome Assembly Chaperones in Sensitivity and Resistance to Proteasome Inhibitors$349,055
R01 · FY2019 · CA · contact PI
Role of TJP1 in Sensitivity and Resistance to Proteasome Inhibitors in Myeloma$345,591
R01 · FY2019 · CA · contact PI
12 Hematologic Malignancies$18,707
P30 · FY2019 · CA · contact PI
12 Hematologic Malignancies$5,455
P30 · FY2019 · CA · contact PI
Proteasome Assembly Chaperones in Sensitivity and Resistance to Proteasome Inhibitors$359,851
R01 · FY2018 · CA · contact PI
Role of TJP1 in Sensitivity and Resistance to Proteasome Inhibitors in Myeloma$356,280
R01 · FY2018 · CA · contact PI
Proteasome Assembly Chaperones in Sensitivity and Resistance to Proteasome Inhibitors$359,851
R01 · FY2017 · CA · contact PI
Role of TJP1 in Sensitivity and Resistance to Proteasome Inhibitors in Myeloma$356,280
R01 · FY2017 · CA · contact PI
Proteasome Assembly Chaperones in Sensitivity and Resistance to Proteasome Inhibitors$374,851
R01 · FY2016 · CA · contact PI
Role of TJP1 in Sensitivity and Resistance to Proteasome Inhibitors in Myeloma$356,280
R01 · FY2016 · CA · contact PI
Role of TJP1 in Sensitivity and Resistance to Proteasome Inhibitors in Myeloma$371,280
R01 · FY2015 · CA · contact PI
M. D. Anderson Cancer Center SPORE in Multiple Myeloma$2,161,999
P50 · FY2014 · CA · contact PI
P3 - TARGETING THE HDM-2 E3 LIGASE IN MULTIPLE MYELOMA$168,658
P50 · FY2014 · CA · contact PI
DEVELOPMENTAL RESEARCH PROGRAM$79,773
P50 · FY2014 · CA · contact PI
ADMINISTRATIVE CORE FACILITY$53,041
P50 · FY2014 · CA · contact PI
M. D. Anderson Cancer Center SPORE in Multiple Myeloma$2,150,500
P50 · FY2013 · CA · contact PI
P3 - TARGETING THE HDM-2 E3 LIGASE IN MULTIPLE MYELOMA$178,931
P50 · FY2013 · CA · contact PI
DEVELOPMENTAL RESEARCH PROGRAM$91,158
P50 · FY2013 · CA · contact PI
ADMINISTRATIVE CORE FACILITY$64,765
P50 · FY2013 · CA · contact PI
M. D. Anderson Cancer Center SPORE in Multiple Myeloma$2,300,000
P50 · FY2012 · CA · contact PI
P3 - TARGETING THE HDM-2 E3 LIGASE IN MULTIPLE MYELOMA$180,934
P50 · FY2012 · CA · contact PI
DEVELOPMENTAL RESEARCH PROGRAM$92,180
P50 · FY2012 · CA · contact PI
ADMINISTRATIVE CORE FACILITY$65,491
P50 · FY2012 · CA · contact PI
M. D. Anderson Cancer Center SPORE in Multiple Myeloma$2,185,000
P50 · FY2011 · CA · contact PI
P3 - TARGETING THE HDM-2 E3 LIGASE IN MULTIPLE MYELOMA$171,210
P50 · FY2011 · CA · contact PI
DEVELOPMENTAL RESEARCH PROGRAM$87,227
P50 · FY2011 · CA · contact PI
ADMINISTRATIVE CORE FACILITY$61,971
P50 · FY2011 · CA · contact PI
M. D. Anderson Cancer Center SPORE in Multiple Myeloma$2,300,000
P50 · FY2010 · CA · contact PI
P3 - TARGETING THE HDM-2 E3 LIGASE IN MULTIPLE MYELOMA$178,869
P50 · FY2010 · CA · contact PI
DEVELOPMENTAL RESEARCH PROGRAM$91,127
P50 · FY2010 · CA · contact PI
ADMINISTRATIVE CORE FACILITY$64,743
P50 · FY2010 · CA · contact PI
Dual Proteasome and MAPK Inhibition in Cancer Therapy$145,322
R01 · FY2008 · CA · contact PI
Dual Proteasome and MAPK Inhibition in Cancer Therapy$89,260
R01 · FY2008 · CA · contact PI
Dual Proteasome and MAPK Inhibition in Cancer Therapy$227,033
R01 · FY2007 · CA · contact PI
PX-171-001-PHASE I STUDY OF ESCALATING DOSES OF PROTEASOME INHIBITOR$42,393
M01 · FY2007 · RR · contact PI
BORTEZOMIB AND PEGYLATED LIPOSOMAL DOXORUBICIN AS THERAPY FOR MULTIPLE MYELOMA$6,565
M01 · FY2007 · RR · contact PI
SB-743971 IN PATIENTS WITH NON-HODGKINS$750
M01 · FY2007 · RR · contact PI
Dual Proteasome and MAPK Inhibition in Cancer Therapy$233,813
R01 · FY2006 · CA · contact PI
BORTEZOMIB AND PEGYLATED LIPOSOMAL DOXORUBICIN AS THERAPY FOR MULTIPLE MYELOMA$22,301
M01 · FY2006 · RR · contact PI
PX-171-001-PHASE I STUDY OF ESCALATING DOSES OF PROTEASOME INHIBITOR$2,974
M01 · FY2006 · RR · contact PI
Dual Proteasome and MAPK Inhibition in Cancer Therapy$239,440
R01 · FY2005 · CA
BORTEZOMIB AND PEGYLATED LIPOSOMAL DOXORUBICIN AS THERAPY FOR MULTIPLE MYELOMA$7,226
M01 · FY2005 · RR
Dual Proteasome and MAPK Inhibition in Cancer Therapy$239,440
R01 · FY2004 · CA
EVALUATION OF PS-341 IN PTS W/ HEMATOLOGIC MALIGNANCIES$0
M01 · FY2000 · RR
EVALUATION OF PS-341 IN PTS W/ HEMATOLOGIC MALIGNANCIES$0
M01 · FY2000 · RR
EVALUATION OF PS-341 IN PTS W/ HEMATOLOGIC MALIGNANCIES$0
M01 · FY2000 · RR
EVALUATION OF PS-341 IN PTS W/ HEMATOLOGIC MALIGNANCIES$0
M01 · FY2000 · RR